This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus erlotinib compared with erlotinib alone in patients with pretreated, non–small cell lung cancer (NSCLC).

The addition of figitumumab to erlotinib did not improve OS in patients with advanced, pretreated, non–adenocarcinoma NSCLC. Clinical development of figitumumab has been discontinued.

READ FULL ARTICLE Curated publisher From Mdlinx